Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients

Arvinas Inc ARVN announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110).

• The data were shared at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.
• The data showed that bavdegalutamide continues to provide evidence of anti-tumor activity and patient benefit in metastatic castration-resistant prostate cancer (mCRPC). 
• Bavdegalutamide reduced prostate-specific antigen (PSA) levels greater than or equal to 50% (PSA50) in 46% of patients with tumors harboring AR T878X/H875Y mutations. 
• Also See: Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients.
• The Company plans to initiate a pivotal trial by year-end 2022.
• Two confirmed partial responses were observed out of seven evaluable patients with AR T878X/H875Y tumor mutations.
• PSA50 rate of 26% (five of 19) in evaluable patients in the subgroup defined as "less pretreated" (having received only one prior hormonal agent and no prior chemotherapy). 
• Most treatment-related adverse events (TRAEs) were mild to moderate, and there were no serious/life-threatening TRAEs in the 113 patients treated at the recommended 420 mg dose.
• Price Action: ARVN shares were down 4.93% at $71.82 during the market session on the last check Tuesday.